Substitute for form 14-	49A/PTO & 1449B/PTO		Com	plete if Known
	SECOND		Application Number	10/690,880
INFO	RMATION DISCLOSURE	•	Filing Date	October 22, 2003
	EMENT BY APPLICANT		First Named Inventor	Nancy M. LEE
	(use as many charts as necessary)		Examiner Name	MARY JO SUSAN DANTON
Sheet	10 40 1		Attorney Docket Number	1034516-000006 Schlapk
	\$\			
	MAR 0 6. 5000 B	U.S.	PATENT DOCUMENTS	
Examiner Initials	Kind Cod (if known		Name of Patentee or App of Cited Document	
		_		

FOREIGN PATENT DOCUMENTS											
							ST	ATUS			
Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Spec

	NON-PATENT LITERATURE DOCUMENTS					
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
WS	Barrier, Alain et al. (2005). Dis Colon Rectum, 48:2238-2248.					
	Barrier, Alain et al. (2005). Oncogene, 24:6155-6164.					
	Bernstein, Carol et al. (1999). Cancer Research, 59:2353-2357.					
	Carlson, M. et al. (2002). Gut, 50:501-506.					
	Chen, Ling-Chun et al. (2004). Cancer Research, 64:3694-3700.					
	De Villiers, Willem J.S. et al. (2000). Cytokine, 12(9):1337-1347.					
	Dolara, Piero <i>et al.</i> (2000). <i>Toxicology</i> , Letters 112-113:415-420.					
	Friedl, A. et al. (1999). The Histochemical Journal, 31:433-441.					
	Fukushima, Kouhei et al. (2002). Digestive Diseases and Sciences, 47(7):1438-1446.					
	Hao, Chun-Yi et al. (2005). Clinical Cancer Research, 11:1400-1407.					
V	Hao, Chun-Yi et al. (2005). Dis Colon Rectum, 48:2329-2335.					
WS	Zou, Tong-Tong <i>et al.</i> (2002). <i>Oncogene</i> , 21:4855-4862.					

	2006.08.29.10:01:37		
Examiner	Walter Schlapkoni -04'00'	Date	
Signature		Considered	i

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

CA 101738.1

Substitute for form 1449A/PTO

E TRADE

Sheet

1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

3

	Complete if Known	
Application Number	10/690,880	_
Filing Date	October 22, 2003	
First Named Inventor	Lee .	
Group Art Unit	1636	_
Examiner Name	unassigned Schlapkohl	
Attorney Docket Number	CPMC-033/01US	

			U.S. P.	ATENT DOCUMENTS	
		U.S. Patent	t Document		Date of Publication of Cited
Examiner Initials*	Cite No.	Number	Kind Code [†] (if known)	Name of Patentee or Applicant of Cited Document	Document MM-DD-YYYY

				FOREIGN PA	ATENT DOCUMENTS		
Examiner Initials*	Cite No.		Foreign Patent Do	cument	Name of Patentee or Applicant of Cited	Date of Publication	
initiais	140.	Office	Number	Kind Code (if known)	Document Document	of Cited Document MM-DD-YYYY	Т
						-	
	 	++-					

		OTHER – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
WS	Bamba, H., et al. High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. Int J Cancer, 83: 470-475, 1999.		
	C2	Bianchi, et al. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res, 54: 861-866, 1994.	
	C3	Buckhaults, et al. Secreted and cell surface genes expressed in benign and malignant colorectal tumors. Cancer Res., 61: 6996-7001, 2001.	
	C4 Coussens and Werb, Inflammation and cancer. Nature, 420: 860-867, 2002.		
	C5	Denhardt, et al. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest, 107: 1055-1061., 2001.	
	C6	Eberhart, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107: 1183-1188, 1994.	
WS	C7	Giordano, et al. Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am J Pathol, 159: 1231-1238, 2001.	

<u>u</u>	C8	Guda, et al. Multistage gene expression profiling in a differentially susceptible mouse colon	
Ø. WS		cancer model. Cancer Lett, 191: 17-25, 2003.	.•
Ws Ws	C9	Gupta, et al. Aspirin, NSAIDS, and colon cancer prevention: mechanisms? Gastroenterology, 114: 1095-1098, 1998.	
	C10	He, et al. Identification of c-MYC as a target of the APC pathway. Science, 281: 1509-1512., 1998.	
	CII	Hegde, et al. Identification of tumor markers in models of human colorectal cancer using a 19,200-element complementary DNA microarray. Cancer Res, 61: 7792-7797, 2001.	
	C12	Hull, et al. Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice. Br J Cancer, 79: 1399-1405, 1999.	
	C13	Ieda, et al. Immunohistochemical analysis of p53 and ras p21 expression in colorectal adenomas and early carcinomas. Surg Today, 26: 230-235, 1996.	
	C14	Inaba, et al. Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted from colon cancer cells. Proc Natl Acad Sci U S A, 100: 2736-2741, 2003.	
	C15	Kitahara, et al. Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia. Cancer Res, 61: 3544-3549, 2001.	-
	C16	Koh, et al. C. Gastrin is a target of the beta-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis. J Clin Invest, 106: 533-539., 2000.	
	C17	Li, et al. Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials. Clin Cancer Res, 7: 3298-3304, 2001.	
	C18	Lin, et al. Identification of AF17 as a downstream gene of the beta-catenin/T-cell factor pathway and its involvement in colorectal carcinogenesis. Cancer Res, 61: 6345-6349, 2001.	
	C19	Loukinova, et al. Growth regulated oncogene-alpha expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism. Oncogene, 19: 3477-3486, 2000.	
	C20	Marnett and DuBois, COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol, 42: 55-80, 2002.	
	C21	Muller-Decker, et al. Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci U S A, 99: 12483-12488, 2002.	
	C22	Muro, et al. Identification of expressed genes linked to malignancy of human colorectal carcinoma by parametric clustering of quantitative expression data. Genome Biol, 4: R21, 2003.	
	C23	Notterman, et al. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res, 61: 3124-3130., 2001.	
WS	C24	Oshima, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87: 803-809., 1996.	

A STATE OF THE STA	ws	C25	Paulsen, et al. Qualitative and quantitative relationship between dysplastic aberrant crypt foci and tumorigenesis in the Min/+ mouse colon. Cancer Res, 61: 50105015., 2001.	
BO		C26	Roy, et al. Distal bowel selectivity in the chemoprevention of experimental colon carcinogenesis by the non-steroidal antiinflammatory drug nabumetone. Int J Cancer, 92: 609-615, 2001.	
		C27	Sherr, The Pezcoller lecture: cancer cell cycles revisited. Cancer Res, 60: 3689-3695., 2000.	
		C28	Siu, et al. The identification of monoclonality in human aberrant crypt foci. Cancer Res, 59: 63-66., 1999.	
•		C29	Tureci, et al. Computational dissection of tissue contamination for identification of colon cancer-specific expression profiles. Faseb J, 17: 376-385, 2003.	
\ V	NS	C30	Williams, et al. Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res, 9: 931-946, 2003.	

	Walter Schlapkohl 2006.08.29 10:30:50	Date	
Signature	0400	Considered	l

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.